Company / Cash & Equivalents
Strata Critical Medical, Inc. Cash & Equivalents History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$18.4M
FY2024
5-year range
$7.0M / $43.3M
FY2021-FY2024
Trend
-34.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $43M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2024 with a 3-year CAGR of +38.3%.
Declined from $43M to $18M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +38.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +38.3%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 34.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $18.4M | -34.1% |
| FY2023 | $27.9M | -35.6% |
| FY2022 | $43.3M | +522.8% |
| FY2021 | $7.0M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026